The US Oncology Network to Standardize on Elekta’s MOSAIQ Oncology Information System

The US Oncology Network (The Woodlands, Texas) – among the largest networks of community-based oncology physicians in the United States – has selected Elekta’s MOSAIQ® Oncology Information System (OIS) as the standard radiation oncology OIS across The Network. In the agreement, The Network committed to purchase five Elekta Infinity™ linear accelerators.The order was booked during Elekta’s third quarter 2011/12.

The recent agreement continues The US Oncology Network’s long-standing relationship with Elekta, as many Network practices are already MOSAIQ users.

“We have found the MOSAIQ OIS software to be very workflow friendly – it increases productivity within our radiation therapy departments,” says Charles Smith PhD, The US Oncology Network Vice President of Cancer Center Services. “Standardizing on the same MOSAIQ version across the entire enterprise will enable us to implement and share best workflow practices and help us to deliver high quality radiation therapy in a cost effective way.”

Dr. Vivek Kavadi, Radiation Oncology Medical Director for The US Oncology Network, says: “This MOSAIQ investment will enable radiation oncologists across The US Oncology Network to better share clinical best practices and support our integrated care platform.”

MOSAIQ is a comprehensive vendor neutral OIS that centralizes radiation oncology and medical oncology patient data into a single user interface, accessible by multidisciplinary teams across multiple locations. MOSAIQ provides hospitals and oncology staff access to the underlying clinical and administrative data, improving both clinical care and operational effectiveness.

source: Elekta

IsoRay's GliaSite Approved for Sale in 31 European Countries

IsoRay Inc. ISR -9.33% , a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced that the GliaSite(R) radiation therapy system, the world's only balloon catheter device used in the treatment of brain cancer, has earned the European CE Mark, allowing immediate sale in 31 European countries. The system's balloon catheter is a landmark technology that allows physicians to treat more patients than ever before with brachytherapy or internal radiation and provides important benefits over other radiation treatment options.

The CE mark designates that the manufacturer conforms with the essential product requirements of the applicable European Commission directives. Granted after a rigorous evaluation process, the CE mark allows a product to be legally marketed in the European Free Trade Association (EFTA) member states as well as the European Union.

IsoRay Chairman and CEO Dwight Babcock commented, "This is a major event for IsoRay as it opens the door to revenue opportunities in international markets where our current distributor previously marketed GliaSite(R) for its prior manufacturer. In addition, it allows us to pursue other distribution opportunities in countries not previously serviced. This historic moment completes the last requirement essential to initiate the international launch of our GliaSite(R) radiation therapy system".

source: IsoRay

New Study Shows Stereotactic Body Radiation Therapy (SBRT) as an Emerging Ablative Therapy for Recurrent Gynecologic Cancer

Fort Myers, FL, May 12, 2012 --(PR.com)-- For the past five years, a small group of Lee County women has been participating in a groundbreaking study using a type of radiation therapy initially used in the treatment of prostate cancer. In the study, presented at the Society for Gynecologic Oncology National Meeting, Southwest Florida physicians Constantine Mantz, M.D., Edward Grendys, M.D., Fadi Abu Shahin, M.D. and James Orr, M.D. recounted the success they have had using Stereotactic Body Radiation Therapy (SBRT) on women with recurrent gynecologic cancers.

Thirty-six patients have been treated using SBRT and have been followed for more than two years. Stereotactic radiation therapy combines radiation therapy with guidance technology. SBRT delivers radiation very precisely to the affected area. The treatment involves sophisticated x-ray technology to capture highly detailed images of the tumor and achieve an extremely degree of accuracy for treatment.

Dr. Orr explains, “We have now developed a new technology for women with recurrent gynecological cancer to alleviate their symptoms and potentially eradicate disease in areas that can be life threatening due to bleeding and infection. It can be used to treat virtually all types of gynecological cancers, including ovarian cancer. The other major benefit to this treatment is that it runs for 10 days instead of months of chemotherapy.”

Because the radiation is delivered so accurately, areas can be retreated if necessary. “While this does not take the place of chemotherapy or wider range radiation, it can be used in conjunction with standard treatment protocols with great success. This is a fantastic way of treating recurrent disease in a manner that has minimal impact on the patient’s quality of life,” Dr. Orr added. “If a woman has had cancer, and has a recurrence, this is an extremely effective tool for treating the cancer quickly and easily, and letting the patient get on with her life.”

source: PR.com